News

February 11, 2019

Cure SMA Awards $150,000 Grant to Laxman Gangwani, PhD, Texas Tech University

Cure SMA Awards $150,000 Grant to Laxman Gangwani, PhD, Texas Tech University

Cure SMA has awarded a $150,000 research grant to Laxman Gangwani, PhD, at the Texas Tech University Health Sciences Center, for his project entitled, "Function of Senataxin as a Protective Modifier of Spinal Muscular Atrophy”.

Dr. Gangwani and his team will study how the...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

January 22, 2019

Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients with SMA

Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients with SMA

Cytokinetics, Incorporated (CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 7, 2019

Genentech, Roche and PTC Therapeutics Provide Update on Regulatory Filing for Risdiplam

Genentech, Roche and PTC Therapeutics Provide Update on Regulatory Filing for Risdiplam

On January 7th, PTC Therapeutics, Inc. provided a corporate update, which will be detailed as part of the company's presentation at the 37th Annual J.P. Morgan...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 7, 2019

Teen and Young Adult Survey Extended Through January 21st

Teen and Young Adult Survey Extended Through January 21st

Are you or a family member between the ages of 12 and 25? Do you want to share your opinion on living with SMA and what is important to you regarding treatment options?

In late November, Cure SMA launched the SMA Teen and Young Adult Clinical Meaningfulness Survey. Anyone with SMA...

READ MORE   |  

Topics: Support & Care, Research, Front Page News

January 2, 2019

Cure SMA Announces Expanded Phase 3 of SMA Industry Collaboration

Cure SMA Announces Expanded Phase 3 of SMA Industry Collaboration

Cure SMA is pleased to announce the launch of an expanded Phase 3 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 26, 2018

December Webinar on SMA Treatments and Clinical Trials Now Available Online

December Webinar on SMA Treatments and Clinical Trials Now Available Online

A recording of the December 13th webinar updating the community on SMA treatments and clinical trials is now available online. A PDF of the webinar presentation is also available for...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

December 20, 2018

2018 Research Year-in-Review

2018 Research Year-in-Review

Over our past fiscal year—from July 1, 2017, to June 30, 2018—Cure SMA has funded over $5 million in new research funding. This funding will be used strategically to help accelerate research, and ensure we are developing treatments for all types, ages, and stages of SMA. The...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 19, 2018

Cure SMA Funding Leads to 16 New Research Publications in 2018

An important goal of our research funding strategy is to share scientific findings with the broader scientific community. Scientists who receive Cure SMA funding often publish their findings in peer-reviewed journals. This means that other scientists can learn from their results, which will pay dividends across the wider landscape of SMA...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 13, 2018

Biogen Issues Q4 Community Statement on Spinraza

Biogen Issues Q4 Community Statement on Spinraza

Bigoen has provided the below community statement on Spinraza. 

Dear Members of the SMA community,

As we approach the two-year anniversary of the U.S. Food and Drug Administration’s (FDA) approval of SPINRAZA® (nusinersen), we want to thank you for your ongoing...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

December 12, 2018

AveXis Issues Community Statement on BLA Acceptance

AveXis Issues Community Statement on BLA Acceptance

AveXis has provided the following community statement on the BLA submission and acceptance for their investigational therapy, AVXS-101 - now known as ZOLGENSMA®.

Dear SMA Community,

We are providing this update to the SMA community in the U.S. at the request of Cure SMA....

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 1 - 10 of 241  12345678910Next

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software